Online citations, reference lists, and bibliographies.
← Back to Search

Multidisciplinary Team Care In Advanced Lung Cancer.

A. Kowalczyk, J. Jassem
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Lung cancer is the most common cause of cancer mortality globally. A vast majority of lung cancer cases are diagnosed at advanced stages. Management of advanced lung cancer requires several diagnostic and therapeutic procedures provided by various specialists. To optimise the entire diagnostic and therapeutic process, a concept of care provided simultaneously by a multidisciplinary team (MDT) has been developed and implemented in specialised centres worldwide. Observational studies suggest that integrated and coordinated care increases adherence to clinical guidelines, significantly shortens the interval from diagnosis to treatment, and may increase survival and quality of life (QoL). Prospective studies are warranted to assess the real impact of MDT on treatment outcomes and to further refine this approach.
This paper references
10.3322/caac.21492
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
F. Bray (2018)
Outcomes of patients presenting to a dedicated rapid access lung cancer clinic.
E. Dunican (2011)
NCCN Guidelines ; Version 7 . 2019 NICE Guidelines
H Liu
10.1016/J.CLLC.2019.07.007
Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer.
K. Mitchell (2019)
10.1016/j.lungcan.2016.04.007
Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
S. Brule (2016)
10.1016/S0140-6736(16)30958-8
Lung cancer: current therapies and new targeted treatments
F. Hirsch (2017)
10.1097/01.sla.0000217629.94941.cf
Epidemiology and Management of Liver Metastases From Colorectal Cancer
S. Manfrédi (2006)
10.1097/COC.0000000000000508
Anaplastic Lymphoma Kinase (ALK)-positive Tumors
R. Gupta (2019)
10.3747/co.19.1069
The importance of multidisciplinary team management of patients with non-small-cell lung cancer.
P. Ellis (2012)
10.1111/j.1445-5994.2009.02019.x
The impact of case discussion at a multidisciplinary team meeting on the treatment and survival of patients with inoperable non‐small cell lung cancer
S. Bydder (2009)
10.1183/09031936.00150813
Multidisciplinary team management in thoracic oncology: more than just a concept?
H. Powell (2014)
10.1016/j.lungcan.2018.07.032
Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study.
E. Stone (2018)
10.1038/bjc.2011.92
Impact of multidisciplinary team management in head and neck cancer patients
P. Friedland (2011)
10.4065/83.5.584
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
J. Molina (2008)
10.1200/JCO.2014.58.6362
Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial.
Marie Bakitas (2015)
10.1136/thoraxjnl-2012-202297
Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007
S. Walters (2013)
10.1371/journal.pone.0126547
Effects of Multidisciplinary Team Care on the Survival of Patients with Different Stages of Non-Small Cell Lung Cancer: A National Cohort Study
Chien-Chou Pan (2015)
10.1093/annonc/mdx757
European Society for Medical Oncology (ESMO) position paper on supportive and palliative care
K. Jordan (2018)
10.1159/000495474
Multidisciplinary Tumor Board Recommendations for Oligometastatic Malignancies: A Prospective Single-Center Analysis
C. Galata (2019)
10.1007/s00520-016-3278-z
Impact of early palliative interventions on the outcomes of care for patients with non-small cell lung cancer
C. Nieder (2016)
10.1053/j.seminoncol.2018.08.007
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
S. Marur (2018)
10.1164/rccm.201307-1269ST
An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer.
M. Gaga (2013)
10.1097/JTO.0b013e31820b88a7
Causes and Consequences of Deviation from Multidisciplinary Care in Thoracic Oncology
R. Osarogiagbon (2011)
10.1038/sj.bjc.6602825
An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer
L. M. Forrest (2005)
10.3892/IJO.25.6.1677
Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
N. Mehta (2004)
10.1007/s00520-017-3821-6
The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study
Jemima T Collins (2017)
10.1001/jamanetworkopen.2019.9702
Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
J. Uhlig (2019)
10.1001/jama.2018.9824
Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non–Small Cell Lung Cancer in the Community Oncology Setting
C. Presley (2018)
10.1016/j.ctrv.2018.10.011
Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors.
A. Wrona (2018)
Cite this article as: Kowalczyk A, Jassem J. Multidisciplinary team care in advanced lung cancer
(2020)
10.1016/j.jtho.2019.07.025
Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.
A. Dingemans (2019)
10.1002/14651858.CD011129.pub2
Early palliative care for adults with advanced cancer.
M. Haun (2017)
10.1016/j.chest.2019.04.115
Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis.
Ming Yang (2019)
10.1016/j.cllc.2018.01.006
Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach
T. Bilfinger (2018)
10.1111/ecc.12768
Multidisciplinary decision‐making regarding chemotherapy for lung cancer patients—An age‐based comparison
K. J. Schulkes (2018)
10.1056/NEJMoa1000678
Early palliative care for patients with metastatic non-small-cell lung cancer.
J. Temel (2010)
10.1016/j.lungcan.2013.08.006
Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer.
T. Yano (2013)
10.1016/j.thorsurg.2014.07.003
The management of non-small cell lung cancer with oligometastases.
R. Downey (2014)
10.1016/j.jtho.2017.08.008
The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non–Small Cell Lung Cancer
E. David (2017)
10.1080/17476348.2018.1486709
Minimally invasive palliative interventions in advanced lung cancer
Christopher Mallow (2018)
10.1016/j.healthpol.2014.09.006
Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes.
J. Prades (2015)
10.1016/j.lungcan.2015.03.020
Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
C. Simmons (2015)
10.1097/JTO.0b013e31802bff56
Multidisciplinary Management of Lung Cancer: How to Test Its Efficacy?
F. Leo (2007)
Effectiveness of decision making at lung cancer multidisciplinary team meetings. Lung Cancer 2011;71:S20
W Storrar (2020)
10.1111/ecc.13004
Performance status agreement assessed by the patient and clinician in a rapid access lung cancer service: Can either predict completion of treatment?
Jemima T Collins (2019)
10.7150/jca.30723
Aging, Cancer and Immunity
Hong Hong (2019)
10.1016/j.jpainsymman.2016.01.003
Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review.
J. King (2016)
10.1002/cncr.26149
Do multidisciplinary team meetings make a difference in the management of lung cancer?
M. Boxer (2011)
10.1016/j.ijrobp.2014.04.007
Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.
Ravi Parikh (2014)
10.18053/jctres.03.2017s3.003
The first steps in the evaluation of a "black-box" decision support tool: a protocol and feasibility study for the evaluation of Watson for Oncology
L. Keikes (2018)
10.1016/j.jtho.2017.12.001
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
N. Lindeman (2018)
10.1016/J.LUNGCAN.2019.06.003
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.
Amanda J W Gibson (2019)
10.1016/S1470-2045(17)30441-2
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
P. Brown (2017)
ICBP Module 1 Working Group. Lung cancer survival and stage at diagnosis in Australia
S Walters (2004)
10.21037/TLCR.2019.04.14
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey.
J. Gregg (2019)
10.1016/j.clineuro.2017.06.022
Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
B. Wang (2017)
10.2196/11087
Using Artificial Intelligence (Watson for Oncology) for Treatment Recommendations Amongst Chinese Patients with Lung Cancer: Feasibility Study
Chaoyuan Liu (2018)
10.1136/bmj.e2718
Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women
E. Kesson (2012)
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study. Lung Cancer 2019;134:141-6
AJW Gibson (2019)
10.1186/s40644-019-0240-6
Accuracy and complications of CT-guided pulmonary core biopsy in small nodules: a single-center experience
Ming-De Huang (2019)
10.1001/jama.2009.1198
Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial.
Marie Bakitas (2009)
10.1016/j.ejcts.2010.01.051
The effect of a multidisciplinary thoracic malignancy conference on the treatment of patients with lung cancer.
R. Freeman (2010)
10.1097/PPO.0000000000000149
Integrating Palliative Care Into the Care of Patients With Advanced Lung Cancer
Jennifer M. Kapo (2015)
10.1016/j.jtho.2018.05.030
Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
C. Rolfo (2018)
10.1200/JOP.19.00357
Management of Brain Metastases in Non-Small-Cell Lung Cancer.
V. Ernani (2019)
10.1016/J.CLLC.2019.05.006
Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis.
D. Mendoza (2019)
10.1097/SPC.0000000000000453
Dietetic assessment and intervention in lung cancer.
I. Phillips (2019)
10.1186/s12913-018-2990-4
Benefits, barriers and opinions on multidisciplinary team meetings: a survey in Swedish cancer care
L. Rosell (2018)
10.1007/s00520-018-4184-3
Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature
M. Ambroggi (2018)
10.4172/2165-7386.1000170
Early Contact with Palliative Care Services: A Randomized Trial in Patients with Newly Detected Incurable Metastatic Cancer
M. Tattersall (2014)
patients following systemic anti - cancer therapy : A 10 year population - based study
JM Kapo (2019)
10.7150/jca.31217
Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
H. Katsura (2019)
Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis.
Chien-Hsin Chen (2018)
10.21037/jtd.2018.09.121
MDT is still important in the treatment of early stage lung cancer.
H. Liu (2018)
10.1016/S0169-5002(11)70057-5
57 Effectiveness of decision making at lung cancer multidisciplinary team meetings
W. Storrar (2011)
10.1200/JCO.2016.70.1474
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update.
B. Ferrell (2017)
Effectiveness of decision making at
W Storrar
10.1111/resp.12520
The effectiveness of lung cancer MDT and the role of respiratory physicians
Charles N Prabhakar (2015)



Semantic Scholar Logo Some data provided by SemanticScholar